224 related articles for article (PubMed ID: 22283680)
1. Three-dimensional patient-specific dosimetry in radioimmunotherapy with 90Y-ibritumomab-tiuxetan.
D'Arienzo M; Cicone F; Chiacchiararelli L; Coniglio A; Delaloye AB; Scopinaro F
Cancer Biother Radiopharm; 2012 Mar; 27(2):124-33. PubMed ID: 22283680
[TBL] [Abstract][Full Text] [Related]
2. Comparison between 2D and 3D dosimetry protocols in 90Y-ibritumomab tiuxetan radioimmunotherapy of patients with non-Hodgkin's lymphoma.
Assié K; Dieudonné A; Gardin I; Buvat I; Tilly H; Vera P
Cancer Biother Radiopharm; 2008 Feb; 23(1):53-64. PubMed ID: 18298329
[TBL] [Abstract][Full Text] [Related]
3. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
Wiseman GA; Kornmehl E; Leigh B; Erwin WD; Podoloff DA; Spies S; Sparks RB; Stabin MG; Witzig T; White CA
J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016
[TBL] [Abstract][Full Text] [Related]
4. High-dose radioimmunotherapy with 90Y-ibritumomab tiuxetan: comparative dosimetric study for tailored treatment.
Cremonesi M; Ferrari M; Grana CM; Vanazzi A; Stabin M; Bartolomei M; Papi S; Prisco G; Ferrucci PF; Martinelli G; Paganelli G
J Nucl Med; 2007 Nov; 48(11):1871-9. PubMed ID: 17978355
[TBL] [Abstract][Full Text] [Related]
5. Accurate dosimetry in 131I radionuclide therapy using patient-specific, 3-dimensional methods for SPECT reconstruction and absorbed dose calculation.
Dewaraja YK; Wilderman SJ; Ljungberg M; Koral KF; Zasadny K; Kaminiski MS
J Nucl Med; 2005 May; 46(5):840-9. PubMed ID: 15872359
[TBL] [Abstract][Full Text] [Related]
6. Feasibility of bremsstrahlung dosimetry for direct dose estimation in patients undergoing treatment with 90Y-ibritumomab tiuxetan.
Arrichiello C; Aloj L; Mormile M; D'Ambrosio L; Frigeri F; Caracò C; Arcamone M; De Martinis F; Pinto A; Lastoria S
Eur J Nucl Med Mol Imaging; 2012 Jun; 39(6):956-66. PubMed ID: 22237846
[TBL] [Abstract][Full Text] [Related]
7. 90Y PET-based dosimetry after selective internal radiotherapy treatments.
D'Arienzo M; Chiaramida P; Chiacchiararelli L; Coniglio A; Cianni R; Salvatori R; Ruzza A; Scopinaro F; Bagni O
Nucl Med Commun; 2012 Jun; 33(6):633-40. PubMed ID: 22407156
[TBL] [Abstract][Full Text] [Related]
8. Radiation dosimetry results from a Phase II trial of ibritumomab tiuxetan (Zevalin) radioimmunotherapy for patients with non-Hodgkin's lymphoma and mild thrombocytopenia.
Wiseman GA; Leigh BR; Erwin WD; Sparks RB; Podoloff DA; Schilder RJ; Bartlett NL; Spies SM; Grillo-López AJ; Witzig TE; White CA
Cancer Biother Radiopharm; 2003 Apr; 18(2):165-78. PubMed ID: 12804042
[TBL] [Abstract][Full Text] [Related]
9. Optimizing radioimmunotherapy by matching dose distribution with tumor structure using 3D reconstructions of serial images.
Flynn AA; Pedley RB; Green AJ; Boxer GM; Boden R; Begent RH
Cancer Biother Radiopharm; 2001 Oct; 16(5):391-400. PubMed ID: 11776756
[TBL] [Abstract][Full Text] [Related]
10. Patient-specific, 3-dimensional dosimetry in non-Hodgkin's lymphoma patients treated with 131I-anti-B1 antibody: assessment of tumor dose-response.
Sgouros G; Squeri S; Ballangrud AM; Kolbert KS; Teitcher JB; Panageas KS; Finn RD; Divgi CR; Larson SM; Zelenetz AD
J Nucl Med; 2003 Feb; 44(2):260-8. PubMed ID: 12571219
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic potential of 90Y- and 131I-labeled anti-CD20 monoclonal antibody in treating non-Hodgkin's lymphoma with pulmonary involvement: a Monte Carlo-based dosimetric analysis.
Song H; Du Y; Sgouros G; Prideaux A; Frey E; Wahl RL
J Nucl Med; 2007 Jan; 48(1):150-7. PubMed ID: 17204712
[TBL] [Abstract][Full Text] [Related]
12. The role of dosimetry in the high activity 90Y-ibritumomab tiuxetan regimens: two cases of abnormal biodistribution.
Aricò D; Grana CM; Vanazzi A; Ferrari M; Mallia A; Sansovini M; Martinelli G; Paganelli G; Cremonesi M
Cancer Biother Radiopharm; 2009 Apr; 24(2):271-5. PubMed ID: 19409050
[TBL] [Abstract][Full Text] [Related]
13. Differences in 3D dose distributions due to calculation method of voxel S-values and the influence of image blurring in SPECT.
Pacilio M; Amato E; Lanconelli N; Basile C; Torres LA; Botta F; Ferrari M; Diaz NC; Perez MC; Fernández M; Lassmann M; Gil AV; Cremonesi M
Phys Med Biol; 2015 Mar; 60(5):1945-64. PubMed ID: 25668639
[TBL] [Abstract][Full Text] [Related]
14. Three-dimensional personalized Monte Carlo dosimetry in 90Y resin microspheres therapy of hepatic metastases: nontumoral liver and lungs radiation protection considerations and treatment planning optimization.
Petitguillaume A; Bernardini M; Hadid L; de Labriolle-Vaylet C; Franck D; Desbrée A
J Nucl Med; 2014 Mar; 55(3):405-13. PubMed ID: 24504053
[TBL] [Abstract][Full Text] [Related]
15. Dosimetry in patients with B-cell lymphoma treated with [(90)Y]ibritumomab tiuxetan or [(131)I]tositumomab.
Sjögreen-Gleisner K; Dewaraja YK; Chiesa C; Tennvall J; Lindén O; Strand SE; Ljungberg M
Q J Nucl Med Mol Imaging; 2011 Apr; 55(2):126-54. PubMed ID: 21386787
[TBL] [Abstract][Full Text] [Related]
16. Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?
Sharkey RM; Brenner A; Burton J; Hajjar G; Toder SP; Alavi A; Matthies A; Tsai DE; Schuster SJ; Stadtmauer EA; Czuczman MS; Lamonica D; Kraeber-Bodere F; Mahe B; Chatal JF; Rogatko A; Mardirrosian G; Goldenberg DM
J Nucl Med; 2003 Dec; 44(12):2000-18. PubMed ID: 14660727
[TBL] [Abstract][Full Text] [Related]
17. Three-step radioimmunotherapy with yttrium-90 biotin: dosimetry and pharmacokinetics in cancer patients.
Cremonesi M; Ferrari M; Chinol M; Stabin MG; Grana C; Prisco G; Robertson C; Tosi G; Paganelli G
Eur J Nucl Med; 1999 Feb; 26(2):110-20. PubMed ID: 9933344
[TBL] [Abstract][Full Text] [Related]
18. MIRD dose estimate report No. 20: radiation absorbed-dose estimates for 111In- and 90Y-ibritumomab tiuxetan.
Fisher DR; Shen S; Meredith RF
J Nucl Med; 2009 Apr; 50(4):644-52. PubMed ID: 19289440
[TBL] [Abstract][Full Text] [Related]
19. Evaluating the Application of Tissue-Specific Dose Kernels Instead of Water Dose Kernels in Internal Dosimetry: A Monte Carlo Study.
Khazaee Moghadam M; Kamali Asl A; Geramifar P; Zaidi H
Cancer Biother Radiopharm; 2016 Dec; 31(10):367-379. PubMed ID: 27996311
[TBL] [Abstract][Full Text] [Related]
20. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
Witzig TE; Gordon LI; Cabanillas F; Czuczman MS; Emmanouilides C; Joyce R; Pohlman BL; Bartlett NL; Wiseman GA; Padre N; Grillo-López AJ; Multani P; White CA
J Clin Oncol; 2002 May; 20(10):2453-63. PubMed ID: 12011122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
